Edison issues review on The Biotech Growth Trust

RNS Number : 6559F

Biotech Growth Trust PLC (The)

22 February 2018

 

London, UK, 22 February 2018

Edison issues review on The Biotech Growth Trust (BIOG)

The Biotech Growth Trust (BIOG) aims to generate long-term capital growth from a concentrated portfolio of global biotech companies. It is jointly managed by Richard Klemm and Geoff Hsu of OrbiMed Capital, who are positive on the outlook for the biotech industry due to a favourable regulatory backdrop, continued industry innovation, an anticipated uptick in M&A activity and reasonable company valuations. The trust is benchmarked against the NASDAQ Biotech index, which it has outperformed in NAV total return terms over 10 years, while trailing over shorter periods. Recent investment performance has been affected by negative newsflow from one of BIOG's top 10 holdings, Celgene, in October 2017.

BIOG's share price discount to cum-income NAV has been in a broadly narrowing trend since Q417. The current 3.6% discount is lower than the averages of the last one, three, five and 10 years of 5.5%, 5.8%, 4.9% and 5.3% respectively. The trust employs a discount control mechanism, with the board aiming to limit the discount to 6% in normal market conditions.  

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Mel Jenner, [phone]

Sarah Godfrey, [phone]

[e-mail]

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        https://www.linkedin.com/company/edison-investment-research 

Twitter           www.twitter.com/Edison_Inv_Res 

YouTube       www.youtube.com/edisonitv 

 

END

 

 

NRADMGZZGZKGRZM